Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Leases (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Current Leases data on record, last reported at $7.1 million in Q4 2025.

  • For Q4 2025, Current Leases rose 4.95% year-over-year to $7.1 million; the TTM value through Dec 2025 reached $7.1 million, up 4.95%, while the annual FY2025 figure was $7.1 million, 4.95% up from the prior year.
  • Current Leases reached $7.1 million in Q4 2025 per APLS's latest filing, up from $7.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $7.4 million in Q2 2025 and bottomed at $3.9 million in Q1 2021.
  • Average Current Leases over 5 years is $5.8 million, with a median of $5.8 million recorded in 2023.
  • Peak YoY movement for Current Leases: surged 51.46% in 2021, then grew 3.39% in 2025.
  • A 5-year view of Current Leases shows it stood at $4.1 million in 2021, then soared by 36.7% to $5.6 million in 2022, then rose by 14.51% to $6.4 million in 2023, then rose by 4.84% to $6.8 million in 2024, then grew by 4.95% to $7.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $7.1 million in Q4 2025, $7.0 million in Q3 2025, and $7.4 million in Q2 2025.